Viatris
🇺🇸 NASDAQ:VTRS
•
Dec 31, 2024
Viatris Q4 2024 Earnings Report
Viatris reported a decline in Q4 2024 revenue and profitability, with efforts to stabilize operations and streamline costs.
Key Takeaways
Viatris posted Q4 2024 revenue of $3.52 billion, reflecting an 8% decline year-over-year. The company reported a GAAP net loss of $516.5 million and adjusted EPS of $0.54. While the Greater China segment showed positive growth, other geographic regions and product categories experienced declines.
Total revenue for Q4 2024 was $3.52 billion, down 8% year-over-year.
GAAP net loss of $516.5 million, with an adjusted EPS of $0.54.
Brands revenue declined 10% year-over-year to $2.17 billion.
Free cash flow of $342.3 million, down 15% compared to Q4 2023.
Viatris Revenue
Viatris EPS
Viatris Revenue by Segment
Viatris Revenue by Geographic Location
Forward Guidance
Viatris expects 2025 revenue between $13.5 billion and $14 billion, with a focus on capital returns and operational efficiency.
Positive Outlook
- Revenue guidance of $13.5 billion to $14 billion for 2025.
- Anticipates $450 million to $550 million in new product revenues.
- Plans for $500 million to $650 million in share repurchases.
- Continued focus on reducing leverage and improving financial flexibility.
- Potential pipeline milestones for late-stage drug candidates.
Challenges Ahead
- Indore facility regulatory issues expected to impact 2025 revenue by $500 million.
- Adjusted EBITDA impact of $385 million due to regulatory actions.
- Ongoing net losses despite cost-cutting efforts.
- Declines in key geographic segments, except for Greater China.
- Increased competitive pressures affecting branded product sales.
Revenue & Expenses
Visualization of income flow from segment revenue to net income